Evidence map›Paper›PMID 37662405›Full record

ArticlebioRxiv : the preprint server for biology2023

Heterologous sarbecovirus receptor binding domains as scaffolds for SARS-CoV-2 receptor binding motif presentation.

Blake M Hauser, Maya Sangesland, Evan C Lam, Kerri J St Denis, Maegan L Sheehan, Mya L Vu, Agnes H Cheng, Alejandro B Balazs, Daniel Lingwood, Aaron G Schmidt

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Blake M HauserRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Maya SangeslandRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Evan C LamRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Kerri J St DenisRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Maegan L SheehanRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Mya L VuRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Agnes H ChengRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Alejandro B BalazsRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Daniel LingwoodRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Aaron G SchmidtRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Ragon Institute of MGH, MIT and Harvard · USHarvard University · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
The Development and Evaluation of Pan-Coronavirus VaccinesP01AI168347 · NIAID · WASHINGTON UNIVERSITY · PI Alba Grifoni · 2022 to 2026
$15.9M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Epitope focusing to the receptor binding motif for a universal coronavirus vaccineR01AI146779 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SCHMIDT, AARON GREGORY · 2019 to 2023
$4.2M
Innate-like BCR activity as a template for universal vaccination against influenza virusR01AI137057 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2018 to 2022
$2.6M
Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Triggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1M
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
$2.0M
AAV Vectored Delivery of Broadly Neutralizing Antibodies with Optimal Innate Functionality Against HIVR01AI174875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2023 to 2024
$1.6M
Epitope focusing using structure-based immunogen design approachesF30AI160908 · NIAID · HARVARD MEDICAL SCHOOL · PI HAUSER, BLAKE MARIE · 2021 to 2023
$91k
NIAID NIH HHS F30 AI160908NIAID NIH HHS P01 AI168347NIAID NIH HHS R01 AI137057NIAID NIH HHS R01 AI146779NIAID NIH HHS R01 AI153098NIAID NIH HHS R01 AI155447NIAID NIH HHS R01 AI174875NIAID NIH HHS T32 AI007245NIDA NIH HHS DP2 DA040254NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

Structure-guided rational immunogen design can generate optimized immunogens that elicit a desired humoral response. Design strategies often center upon targeting conserved sites on viral glycoproteins that will ultimately confer potent neutralization. For SARS-CoV-2 (SARS-2), the surface-exposed spike glycoprotein includes a broadly conserved portion, the receptor binding motif (RBM), that is required to engage the host cellular receptor, ACE2. Expanding humoral responses to this site may result in a more potently neutralizing antibody response against diverse sarbecoviruses. Here, we used a "resurfacing" approach and iterative design cycles to graft the SARS-2 RBM onto heterologous sarbecovirus scaffolds. The scaffolds were selected to vary the antigenic distance relative to SARS-2 to potentially focus responses to RBM. Multimerized versions of these immunogens elicited broad neutralization against sarbecoviruses in the context of preexisting SARS-2 immunity. These validated engineering approaches can help inform future immunogen design efforts for sarbecoviruses and are generally applicable to other viruses.

Indexed as

coronavirusimmune imprintingSARS-CoV-2

Identifiers

PMID37662405
PMCPMC10473630
OpenAlexW4386094881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.